Table 1.

Definition of prostate cancer risk groups used in this study (adapted from PCBaSe Sweden)^{11 12}

Risk categories	Clinical stage	Prostate specific antigen (ng/mL)	Biopsy Gleason
Group 1 (low risk)	T1-2 N0/Nx M0/Mx	≤10	≤6 or WHO 1
Group 2 (intermediate risk)		10-20	7 or WHO 2
Group 3 (high risk)	T3 N0/Nx M0/Mx	20-50	≥8 or WHO 3
Group 4 (metastatic)	T4 N+ M+	>50	—